FDA Adverse Event Injury Summary report: N

REPLACEMENT HEART VALVE

MDR report key: 3870799 · Received June 12, 2014

Report

Report Number
2015691-2014-01378
Event Type
Injury
Date Received
June 12, 2014
Date of Event
May 14, 2014
Report Date
May 14, 2014
Manufacturer
EDWARDS LIFESCIENCES
Product Code
DYE
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
SZ
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

IT WAS LEARNED THAT THIS DEVICE WAS EXPLANTED DUE TO DEGENERATION. STRUCTURAL VALVE DETERIORATION (SVD), OR DEGENERATION, IS THE MOST COMMON REASON FOR BIOPROSTHESIS EXPLANT AND ENCOMPASSES MULTIPLE FAILURE MODES, INCLUDING CALCIFICATION, NON-CALCIFIC DEGENERATION, DEHISCENCE, CUSP THICKENING OR FIBROSIS, OR A COMBINATION OF THESE. SUCH FAILURE MODES MAY OCCUR SINGULARLY OR CONCOMITANTLY. THE SPECIFIC NATURE OF THIS DEGENERATION CANNOT BE CONFIRMED WITHOUT THE SUBJECT DEVICE. NO FURTHER ACTIONS ARE POSSIBLE WITH THE AVAILABLE INFORMATION.

Additional Manufacturer Narrative · 1

IN THIS CASE, THERE IS INSUFFICIENT INFORMATION TO CONCLUSIVELY DETERMINE THE ROOT CAUSE OF THIS EVENT. THERE HAVE NOT BEEN ANY ALLEGATIONS OF A MALFUNCTION OR DEFICIENCY RELATED TO THE EDWARDS VALVE. CONTINUED ATTEMPTS ARE BEING MADE TO OBTAIN ADDITIONAL DETAILS REGARDING THIS CASE. A SUPPLEMENTAL MDR WILL BE SUBMITTED IN THE EVENT ANY NEW INFORMATION IS RECEIVED.

Description of Event or Problem · 1

AS REPORTED, THIS PATIENT REQUIRED A VALVE-IN-VALVE PROCEDURE AFTER APPROXIMATELY 9-10 YEARS (EXACT IMPLANT DATE IS UNKNOWN) WITHIN AN EXISTING EDWARDS BIOPROSTHETIC VALVE. THE REASON FOR REDO-AVR IS UNKNOWN. THE PATIENT REPORTED TO HAVE A "RARE DISEASE" AND COULD NOT UNDERGO SURGICAL VALVE REPLACEMENT. A TRANSCATHETER HEART VALVE WAS IMPLANTED SUCCESSFULLY. THE PATIENT IS REPORTED AS STABLE. NO OTHER DETAILS HAVE BEEN PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
347629 REPLACEMENT HEART VALVE DYE EDWARDS LIFESCIENCES UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 50 YR Hospitalization| R